newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TIGENIX NV

  • Financial Performance:

    • Commercial investment increased to approximately ¥100 billion this year, with plans for further increases next year to support the full-year commercialization of three new products.
    • The company is executing a cost-saving and transformation program (de-layering management, centralizing functions) to fund the incremental investment in new launches and R&D.
    • Net debt-to-adjusted EBITDA ratio is currently 2.5x, with a target to reduce it to 2.0x prior to the U.S. NTZV biosimilar entry.
    • Dividend policy remains progressive, with approximately 40% of free cash flow currently allocated to shareholder returns.
    • Operating profit margins in the current "Horizon 1" phase are being protected as savings are reinvested into growth; profit accretion from new launches is not expected until "Horizon 2."
  • Guidance and Future Outlook:

    • The company outlines a "Horizon 1" strategy focused on organizational transformation and low organic growth to protect margins, followed by "Horizon 2" for sustainable growth as new assets reach scale and the second wave of launches commences.
    • Zazacitinib (Zazacitinib) approval for psoriasis is expected in March 2024, with subsequent data expected for psoriatic arthritis and IBD indications.
    • Management anticipates the three new launches (Mimrylo, Zurzo, Zazacitinib) will serve as the foundation for future growth, while the remainder of the mature portfolio (including Entresto) is expected to provide stability rather than significant growth drivers.
    • A Capital Markets Day on December 11th will detail the long-term strategy regarding portfolio depth and growth horizons.
  • Business Segments and Product Lines:

    • Oncology/Polycythemia Vera: Mimrylo is already launched and performing well.
    • Neuroscience/Narcolepsy: Zurzo (daridorexant) is launched and performing well; TAC-360 (orexin-2 agonist) is in the pipeline for broader sleep disorders and attention deficit indications.
    • Dermatology: Zazacitinib is in the late-stage development phase, with Phase III data for psoriasis pending and potential Phase III initiation for IBD pending Crohn's disease data.
    • Gastroenterology: Zazacitinib is being developed for Ulcerative Colitis (UC) and Crohn's disease (CD); UC data showed efficacy at a middle dose but a bell-shaped curve at higher doses, while CD data is expected to inform the final go/no-go decision.
    • Pipeline Depth: Strategy focuses on building depth within existing franchises (Gastro, Neuroscience, Oncology) rather than entering new therapeutic areas, with a specific emphasis on early-stage assets to complement late-stage programs.
  • Market and Competitive Landscape:

    • Dermatology: The oral treatment segment represents ~10% of the U.S. market with significant growth potential; Zazacitinib demonstrates superior efficacy (2.5x greater PASI 100 effect vs. competitor upadacitinib) and a favorable profile (no food restrictions, fast onset).
    • Sleep Disorders: Takeda holds a leadership position in orexin biology; Type 1 narcolepsy is a unique deficiency-driven indication, while other uses (Type 2, OSA, fatigue) involve normal orexin levels and different dosing strategies.
    • Innovation Sources: China has transitioned from a "fast-follow" market to a source of high-quality innovative assets, which Takeda leverages for pipeline development and clinical trials despite geopolitical considerations.
    • Competition: The company acknowledges competition from J&J's oral psoriasis agent and other oral agents in IBD but maintains confidence in the distinct efficacy and profiles of its assets.
  • Risks and Challenges:

    • Financial Risk: Significant upfront commercial investment required for three major launches may pressure short-term profitability before cost savings and launch revenues fully annualize.
    • Clinical Risk: Zazacitinib's IBD program faces complexity due to a non-linear (bell-shaped) dose-response curve in UC, requiring careful evaluation of CD data before finalizing dosing and development strategy.
    • Portfolio Risk: Dependence on the mature Entresto franchise amidst eventual patent expiration (LOE), necessitating a successful transition to the new product cohort.
    • Geopolitical: Potential risks associated with reliance on China for R&D and clinical development due to current geopolitical tensions.
  • Management Commentary and Tone:

    • CEO Julie Kim: Expressed high confidence in the pipeline's potential, specifically addressing investor concerns about growth post-Entresto LOE. Tone is strategic and focused on long-term "depth" in franchises.
    • CFO Milano Furuno: Adopted a cautious tone regarding near-term profit accretion, emphasizing the reinvestment of savings into the pipeline and commercialization rather than immediate bottom-line improvements.
    • Head of R&D Andy Plump (announcing retirement): Highlighted the "pace of change" in the industry, citing AI and rapid scientific translation as the primary drivers and challenges for future R&D efficiency.
    • Overall Tone: Confident in the science and launch readiness, transparent about the transitional financial costs, and committed to a disciplined capital allocation strategy.
  • Analyst Questions and Answers:

    • Launch Preparation: Management confirmed resources are allocated to the three launches, noting strong performance for Mimrylo and Zurzo to date.
    • Dermatology Demand: Analysts asked about dermatologists' readiness for oral alternatives; management cited the fear of injectables and the superior efficacy of Zazacitinib as key drivers for patient uptake.
    • Funding Strategy: Clarified that the ¥100 billion investment is funded by an ongoing transformation program rather than external financing, with net debt reduction continuing in parallel.
    • Izazacitinib IBD Data: When asked if the bell-shaped dose curve was disappointing, management responded that the middle-dose efficacy is encouraging and the Crohn's data will be critical for the final decision.
    • M&A Strategy: Clarified that acquisition targets will focus on earlier-stage assets to add depth to current franchises (Gastro, Neuroscience, Oncology) rather than late-stage commercial products or new therapeutic areas.
    • Orexin Science: Differentiated the biology of Type 1 narcolepsy (deficiency) from other indications (normal levels) and outlined a plan for distinct molecules (TAC-360, TAC-495) tailored to different indications and commercial models.
  • Other Key Points:

    • Andy Plump is scheduled to retire next year; he emphasized that the industry's biggest challenge is navigating the speed of scientific and operational change.
    • The company is exploring dual-pharmacology (orexin-1/2) as a next-generation approach beyond current orexin-2 agonists.
    • The upcoming Capital Markets Day will be a major focus for explaining the transition from "Horizon 1" to "Horizon 2" growth.
    • Zazacitinib has no food restrictions and a strong durability profile, distinguishing it from existing oral psoriasis treatments.
Company
TIGENIX NV
Keywords
TIGENIX NV